Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Karen Hastings

Karen Hastings

Professor, Immunobiology | Professor | Professor, Clinical Translational Sciences | Professor, Cancer Biology - GIDP | Member of the Graduate Faculty | Chair, Department of Dermatology | Professor, Dermatology

College of Medicine - Phoenix

Collaboration(22)

Denise Roe
Bonnie LaFleur
Shenfeng Qiu
Taben Hale
Anne Cress

Page 1 of 5

Grants(23)

T Cell Sculpting of the Neoantigen Landscape in Cutaneous Squamous Cell Carcinoma
Active·2024·$300K·
External
Principal Investigator (PI)
cancer immunotherapy, t cell biology, cancer genomics, skin cancer research, neoantigens
PVAHCS - IPA for Anne Macy (PI: Karen Hastings MD, PhD)
Active·2024·$90.4K·
External
Principal Investigator (PI)
healthcare, medical research, health services, administrative, clinical trials
Neoantigen-specific T Cells in a Novel Cutaneous Squamous Cell Carcinoma Mode
Active·2023·$0 / $106.7K·
External
Co-Investigator (COI)
cancer immunotherapy, skin cancer, immunology, oncology, tumor immunology
Immunoediting in Cutaneous Squamous Cell Carcinoma
Active·2023·$0 / $86K·
External
Co-Investigator (COI)
immunotherapy, skin cancer, tumor immunology, cancer immunology, immunological response
PVAHCS - IPA for Lauren Herrmann (PI: Karen Hastings MD, PhD)
Active·2023·$65.8K·
External
Principal Investigator (PI)
healthcare, medical, research, administration, clinical

Page 1 of 5

Publications(66)

Recent

Distinct sets of molecular characteristics define tumor-rejecting neoantigens

2024

cancer immunotherapy, neoantigens, tumor rejection, molecular characteristics, tumor immunity

HCV-and HBV-mediated liver cancer converge on similar transcriptomic landscapes and immune profiles.

2024

liver cancer, transcriptomic analysis, viral hepatitis, immune system, cancer research

045 Characteristics of tumor-rejecting neoantigens identified in a physiologically relevant cutaneous squamous cell carcinoma model

2024

neoantigens, squamous cell carcinoma, cancer immunotherapy

Tumor immune microenvironment permissive to metastatic progression of ING4-deficient breast cancer

2024

Major histocompatibility complex class II in the tumor microenvironment: functions of nonprofessional antigen-presenting cells

2023

tumor microenvironment, antigen-presenting cells, major histocompatibility complex, immune response, cancer immunotherapy

137 Majority of mutations in cutaneous squamous cell carcinoma are unique to individual tumors

2023

genomics, cancer, mutation, skin, tumor

084 Neoantigen-specific T cell responses constrain cutaneous squamous cell carcinoma

2023

cancer immunotherapy, tumor immunology, neoantigens, t cell therapy, skin cancer immunology

High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition

2022

melanoma, immune checkpoint, gilt expression, metastatic, survival

Cancer neoantigens: challenges and future directions for prediction, prioritization and validation

2022

cancer, neoantigens, prediction, validation, challenges

NeoScore integrates characteristics of the neoantigen: MHC class I interaction and expression to accurately prioritize immunogenic neoantigens

2022

neoantigen characterization, immunogenicity prediction, mhc class i interaction, neoscore prioritization, neoantigen expression